Business Deal Lipigon Acquires Certain LNA plus Based Antisense Drug Candidates from Secarna
Lipigon Pharmaceuticals has entered into a research, development and transfer agreement with Secarna Pharmaceuticals. Under the terms of the agreement, Lipigon Pharmaceuticals will continue to develop the acquired antisense drug candidates targeting the Angptl gene family.
Munich/Germany – Secarna Pharmaceuticals (Secarna), a biopharmaceutical company, via its LNA plus platform, has recently announced that the Company signed a Research, Development and Transfer Agreement with Lipigon Pharmaceuticals (Lipigon).
Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna’s proprietary LNA plus platform, including the corresponding patent portfolio. The antisense oligonucleotide candidates targeting the Angptl gene family for the treatment of cardiovascular and metabolic diseases were previously generated by Secarna and Lipigon under a target validation and drug discovery collaboration. Going forward, Lipigon will fund and continue the development of the acquired assets and Secarna receives payments customary for such a transaction. Financial details were not disclosed.
Inhibiting the Angptl gene family members Angptl3 and Angptl4 with Secarna’s LNA plus based antisense oligonucleotides has shown to positively affect plasma lipid levels. Therefore, safe and effective drug candidates addressing these targets have the potential to become novel treatments of orphan diseases such as Familial Chylomicronaemia Syndrome or Homozygote Familial Hypercholesterolemia, but also more common cardiovascular, metabolic liver, kidney diseases or diseases as dyslipidaemia.
“For the past two years, we have collaborated with our colleagues at Lipigon under a highly productive discovery and research partnership. We are excited that Lipigon has selected therapeutic lead candidates generated from Secarna’s LNA plus platform and will now swiftly progress them through the next stages of development”, said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals.
“Antisense-based therapeutics has gained strong industry interest over the past five to seven years as evidenced by major licensing and acquisitions transactions. We are very pleased that our successful collaboration with Secarna has generated fully optimised, patented LNA plus antisense drug candidates ready to enter late stage pre-clinical development and GMP manufacturing,” said Stefan K. Nilsson, CEO and Co-founder of Lipigon.
About Secarna’s Proprietary Drug Discovery Platform, LNA Plus
Secarna’s proprietary third-generation antisense oligonucleotide (ASO) platform, LNA plus, which encompasses all aspects of drug discovery and pre-clinical development, enables the company to discover novel antisense-based therapies for challenging or currently undruggable targets. Secarna’s platform and ASOs have previously been validated by numerous in-house projects as well as in several academic and industry collaborations.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46459463)